BioSpace News Archive

Boundless Bio today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

AnHeart Therapeutics announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Company’s research and development programs.

Ferring Pharmaceuticals and Rebiotix today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021.

CytoDyn Inc. today announced that Brazil’s regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the start of an additional Phase 3 CD16 clinical trial of leronlimab.

Pluristem Therapeutics Inc., a leading biotechnology company, issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.

BioChain Institute, a leader in high quality processed bio-sample products, announced an expanded line of Next Generation Sequencing characterized bio-samples encompassing a variety of cancer-related mutations available for preclinical drug development and as reference samples for CLIA labs.

9 Meters Biopharma, Inc. today announced that the Company’s CEO, John Temperato is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings.

Checkpoint Therapeutics, Inc. today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET.

Akari Therapeutics, Plc today announced its financial results for the second quarter of 2021, as well as recent clinical progress.

Leap Therapeutics, Inc. today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock